PubRank

F Clavel

Author PubWeight™ 116.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 1987 11.79
2 Isolation of a new human retrovirus from West African patients with AIDS. Science 1986 7.97
3 Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002 5.83
4 Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol 1990 4.38
5 HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994 4.15
6 Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999 3.43
7 A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol 1992 3.39
8 Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996 2.95
9 Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998 2.92
10 Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 1987 2.86
11 Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 1998 2.82
12 Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998 2.55
13 Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol 1995 2.45
14 Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med 1987 2.32
15 Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000 2.27
16 Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology 1985 2.23
17 Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons. J Virol 1992 2.15
18 Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001 2.13
19 Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001 2.08
20 A single-stranded gap in human immunodeficiency virus unintegrated linear DNA defined by a central copy of the polypurine tract. J Virol 1991 1.90
21 Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001 1.79
22 Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001 1.62
23 Relative validity and reproducibility of a French dietary history questionnaire. Int J Epidemiol 1997 1.54
24 Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999 1.52
25 Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet 1987 1.49
26 Deficient LAV1 neutralising capacity of sera from patients with AIDS or related syndromes. Lancet 1985 1.48
27 Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res Hum Retroviruses 1994 1.46
28 Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 1994 1.46
29 A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis. Virology 1995 1.38
30 Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol 1997 1.38
31 Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Virology 1996 1.26
32 A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells. J Immunol 1986 1.25
33 Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999 1.20
34 Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol 1999 1.13
35 Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS 1997 1.10
36 Helping people to stop smoking: randomised comparison of groups being treated with acupuncture and nicotine gum with control group. Br Med J (Clin Res Ed) 1985 1.07
37 Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis 2001 1.03
38 The replicative impairment of Vif- mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis. J Gen Virol 1998 1.02
39 Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 1999 1.02
40 Reversion of a polymerase-defective integrated HIV-1 genome. AIDS Res Hum Retroviruses 1993 0.96
41 Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999 0.95
42 Variations in the risk of breast cancer associated with a family history of breast cancer according to age at onset and reproductive factors. J Clin Epidemiol 1993 0.92
43 Exposure to vinyl chloride monomer: report on a cohort study. Br J Ind Med 1987 0.89
44 Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses 2001 0.88
45 Breast cancer and oral contraceptives: a review. Contraception 1985 0.87
46 Occupational exposure and cancer of the pancreas: a review. Br J Ind Med 1991 0.87
47 Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature. Gut 1987 0.87
48 Familial risk of breast cancer and abortion. Cancer Detect Prev 1994 0.84
49 Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. AIDS 2000 0.84
50 Occupational risk factors for cancer of the pancreas: a case-control study. Br J Ind Med 1990 0.84
51 Lung in acquired immune deficiency syndrome: infectious and immunological status assessed by bronchoalveolar lavage. Bull Eur Physiopathol Respir 1986 0.82
52 [Tobacco withdrawal. Comparison of the efficacy of various methods. Intermediate results of a comparative study]. Presse Med 1984 0.81
53 Familial susceptibility to breast cancer: a complex inheritance. Int J Cancer 1989 0.80
54 Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Ann Oncol 2013 0.80
55 Alcohol, beer and cancer of the pancreas. Int J Cancer 1990 0.80
56 More on coffee and pancreatic cancer. N Engl J Med 1987 0.79
57 Inhibition of HIV type 1 reverse transcriptase assay by nucleases produced by contaminating mycoplasmas. AIDS Res Hum Retroviruses 1994 0.78
58 Plasma concentrations of fatty acids in nine European countries: cross-sectional study within the European Prospective Investigation into Cancer and Nutrition (EPIC). IARC Sci Publ 2002 0.78
59 Familial risk of breast cancer in a French case-control study. Cancer Detect Prev 1994 0.78
60 Lymphadenopathy associated virus and its etiological role in AIDS. Princess Takamatsu Symp 1984 0.77
61 Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. Virology 1995 0.76
62 Alveolar macrophage phagocytosis in sarcoidosis. The role of activated lymphocytes. Ann N Y Acad Sci 1986 0.76
63 Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. HIV Clin Trials 2002 0.75
64 [Breast cancer and use of antihypertensive drugs and oral contraceptives: results of a case-control study (author's transl)]. Bull Cancer 1981 0.75
65 Summary statement on disease activity assessment. Ann N Y Acad Sci 1986 0.75
66 [Epidemiological surveys]. Rev Prat 1983 0.75
67 [Analysis of silicone testicular implants after explantation]. J Urol (Paris) 1982 0.75
68 [Relation between mortality in cancer of the pancreas and food and tobacco consumption in France]. Biomed Pharmacother 1982 0.75
69 [Viral etiology of AIDS]. Rev Prat 1986 0.75
70 [Epidemiologic surveys]. Rev Prat 1989 0.75
71 Compliance with the urine marker PABAcheck in cancer epidemiology studies. IARC Sci Publ 2002 0.75
72 [Evaluation of a self-assessment questionnaire with optical reader in a cohort study]. Rev Epidemiol Sante Publique 1995 0.75
73 Association between breast cancer and family malignancies. Eur J Cancer 1991 0.75
74 [Techniques and methods in public health applied in oncology]. Bull Cancer 2001 0.75
75 [LAV type II: a second retrovirus associated with AIDS in West Africa]. C R Acad Sci III 1986 0.75
76 [Analysis of risk factors in arteriosclerosis obliterans of the lower extremities. Preliminary results]. Union Med Can 1981 0.75